Stay updated on Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial page.

Latest updates to the Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page footer revision label has been updated from **Revision: v3.5.0** to **Revision: v3.5.3**.SummaryDifference0.0%

- Check51 days agoChange DetectedThe page now shows a revision label, Revision: v3.5.0, replacing the previous Revision: v3.4.3.SummaryDifference0.0%

- Check65 days agoChange DetectedThe page now displays the latest revision label (v3.4.3) and removes the previous revision (v3.4.2).SummaryDifference0.0%

- Check87 days agoChange DetectedThe page shows a revision bump from v3.4.1 to v3.4.2 with no changes to study content, eligibility criteria, endpoints, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check94 days agoChange DetectedA minor revision update from v3.4.0 to v3.4.1; core study details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check108 days agoChange DetectedMinor UI and text updates: glossary show/hide controls were added, and footer text was updated to reflect capitalization and a new revision tag (v3.4.0).SummaryDifference0.2%

Stay in the know with updates to Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial page.